

Coverage and Effectiveness of mRNA COVID-19 Vaccines among Veterans

Authors: Yinong Young-Xu, ScD, MA, MS^{1,2}, Caroline Korves, ScD¹, Jeff Roberts, MD³, Ethan I. Powell, BA¹; Gabrielle M. Zwain, BA¹, and Jeremy Smith, MS¹, Hector S. Izurieta, MD, MPH, PhD³

Author Institutions/Affiliations:

1. White River Junction Veterans Affairs Medical Center, White River Junction, VT
2. Geisel School of Medicine at Dartmouth, Hanover, NH
3. Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, White Oak, MD

Corresponding Author:

Yinong Young-Xu
Veterans Affairs Medical Center
215 North Main Street
White River Junction, VT 05009
Yinong.Young-Xu@va.gov

Acknowledgements of research support for the study: This project was funded by the United States Food and Drug Administration through an interagency agreement with the Veterans Health Administration

Disclaimer: This article represents the author's best judgement, and should not bind or obligate the FDA, the VA, or any other institution.

Conflict of Interest Declaration: The authors, YYX, CK, EP, GZ, JS, acknowledge having received funding from Pfizer for other research projects but not this one.

Word count: 2,782/3,000

Abstract word count: 250 words

Number of Tables and/or Figures: 5 Tables and Figures

Key words: COVID-19; mRNA vaccine; SARS-CoV-2; Veterans; vaccine effectiveness

Abstract: (285 words)

Importance: The effectiveness of mRNA vaccination in a large and diverse American population, with older age and higher co-morbidity has not been assessed.

Objective: To describe the scope of the mRNA vaccination rollout among the diverse U.S. Veterans population, and to study the mRNA COVID-19 vaccine effectiveness (VE) against infection, symptomatic disease, hospitalization, and death.

Methods: Vaccination histories were obtained from medical records to determine if patients tested for SARS-CoV-2 were unvaccinated, partially vaccinated (first dose of mRNA COVID-19 vaccine), or fully vaccinated (two doses) at time of testing. First, coverage with any COVID-19 vaccination was described for all Veterans enrolled in Veterans Health Administration (VHA). Second, to evaluate VE, a matched test-negative case-control evaluation was conducted utilizing SARS-CoV-2 positive (cases [n=16,690]) and SARS-CoV-2 negative (controls [n=61,610]) tests from Veterans aged ≥ 18 years old who routinely sought care at a VHA facility and were tested from December 14, 2020, through March 14, 2021. VE was calculated from odds ratios (ORs) with 95% confidence intervals (CI).

Results:

By March 7, 2021, among 6,170,750 Veterans, 1,547,045 (23%) received at least one COVID-19 vaccination. mRNA COVID-19 VE against infection, regardless of symptoms, was 94% (95% CI 92-95) and 58% (95% CI 54-62) for full and partial vaccination (vs. no vaccination), respectively. VE against infection was similar across subpopulations, and it was not significantly different from VE against symptomatic disease. VE against COVID-19-related hospitalization and death for full vs. no vaccination was 89% (95% CI 81-93) and 99% (95% CI 87-100), respectively.

Conclusions and Relevance:

The VHA's efficient and equitable distribution of effective vaccines decreased COVID-19 infections, hospitalization, and mortality similarly for all Veterans, including Veterans with low income, homeless Veterans, immunocompromised, the elderly, minorities, and rural Veterans thus reducing health inequalities.

INTRODUCTION

On December 11, 2020, the United States (U.S.) Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine, for the prevention of coronavirus disease 2019 (COVID-19) for individuals 16 years and older(1). One week later, the FDA issued an EUA for Moderna COVID-19 Vaccine, developed by Moderna, for individuals 18 years and older(2); both vaccines are mRNA vaccines. Prior to these EUAs, the pandemic's impact on Veterans enrolled in the Veterans Health Administration (VHA), like elsewhere in the US, was devastating. Approximately 207,000 COVID-19 cases had been reported by the end of 2020 among VHA enrolled Veterans(3). Additionally, the burden of COVID-19 cases was distributed disproportionately among racial and ethnic minorities and could not be explained by underlying chronic conditions. About 35% and 13% of infected Veterans were Black and Hispanic, although they comprised only 13% and 7% of the total VHA patient population, respectively. Over 10,000 of these patients died(3).

The VHA has worked closely with the Centers for Disease Control and Prevention (CDC) and other federal partners to provide COVID-19 vaccines to Veterans as quickly and safely as possible. On March 24, 2021 the success of the VHA vaccination program prompted the U.S. Congress to pass the "Strengthening and Amplifying Vaccination Efforts to Locally Immunize All Veterans and Every Spouse Act" which authorized the Department of Veterans Affairs (VA) to expand its vaccination effort beyond enrolled Veterans(4). Rapid deployment of the vaccination program was accompanied by VHA's nationwide SARS-CoV-2 testing effort, which aimed to test and record both symptomatic and asymptomatic patients across all VHA facilities. Combined with accurate and timely recording of vaccination, this created an opportunity for a robust and well-powered test-negative case-control analysis.

Aiming to describe the extent of vaccination coverage and evaluate the effectiveness of both mRNA vaccines in a diverse population that included socio-economically disadvantaged and medically high-risk individuals, we focused this study on the first three months of the vaccination effort in the VHA, thus the analysis excluded data on the Janssen COVID-19 Vaccine.

METHODS

The study protocol was approved by the institutional review board of the VA Medical Center in White River Junction, VT.

Data Source

The VHA is the largest integrated health care system in the U.S., providing comprehensive care to over nine million Veterans at more than 171 medical centers and 1,112 outpatient sites of care(4). We analyzed electronic medical record data from the VHA Corporate Data Warehouse (CDW). The CDW contains patient-level information on all patient encounters, treatments, prescriptions (including vaccinations), and laboratory results rendered in VHA medical facilities.

Study Design

First, vaccination coverage, defined as having at least one COVID-19 vaccination administered at a VHA facility between December 14, 2020 and March 7, 2021, was described for the population of VHA enrollees. Second, we conducted a test-negative design (TND) case-control study to evaluate mRNA COVID-19 VE against infection, irrespective of symptoms, and a case-control study to evaluate VE against COVID-19-related hospitalization and death. The study population included Veterans ages 18 years and older, with residence in a U.S. state or Washington, D.C., who presented for SARS-CoV-2 PCR or antigen testing at a VHA outpatient or emergency room facility, or had testing within one day of hospitalization, during the study period (December 14, 2020, and March 7, 2021). Patients were required to have had VHA enrollment for at least two years prior to the study period and at least one inpatient or two outpatient visits in the past two years. Individuals meeting any of the following criteria were excluded: a COVID-19 diagnosis and/or a positive SARS-CoV-2 antigen or PCR test at any time between February 2020 and study initiation (December 14, 2020); hospitalization more than one day prior to testing; incomplete VHA medical records.

For the TND case-control study to assess VE against infection, positive SARS-CoV-2 tests from qualifying patients were classified as cases. Negative SARS-CoV-2 tests from qualifying patients served as controls, and a maximum of four controls were matched to each case based on Health and Human Services (HHS) geographic region, and testing date (within 14 days of case testing date) as both of these factors are related to local disease

burden, likelihood of testing positive for SARS-CoV-2, and vaccine exposure status. A TND case-control study to assess VE against symptomatic disease was also conducted. Within the population of patients with a SARS-CoV-2 test performed, a case-control study was also conducted to assess VE in preventing COVID-19-related hospitalization and death. For these analyses, cases were those who tested positive and were hospitalized (or died within 30 days of testing positive), and controls were Veterans who were tested negative and did not have the outcome of interest. Up to four controls were matched to each case based on geographic region and testing date.

Exposure, Outcome and Covariate Assessment

Vaccination status was based on records of mRNA COVID-19 vaccination at a VHA facility from December 14, 2020- February 28, 2021. A person was classified as unvaccinated until the day prior to the first vaccination, partially vaccinated from day 7 after the first vaccination until the day prior to the second vaccination, and fully vaccinated starting at 7 days after the second vaccination (*Supplemental Figure 1*). Days 0-6 after the first and second doses were excluded from all analyses. Vaccination status was determined at the date of testing.

For the TND case-control study to assess VE against infection, medical records were used to identify cases (positive tests) and controls (negative tests). For the TND case-control study to assess VE against symptomatic disease, Veterans who tested positive were further restricted to those who, on the day of testing, had evidence of at least one COVID-19 symptom (*Supplemental Table 1*). For the case-control study for hospitalization and death, a COVID-19-related hospitalization was identified by the presence of an admission and discharge diagnosis of COVID-19 occurring any time after the first positive SARS-CoV-2 test. A death occurring in hospital with a COVID-19 discharge diagnosis or a death occurring within 30 days of a positive SARS-CoV-2 test was classified as a COVID-19-related death; controls were drawn from patients with a negative SARS-CoV-2 test who were not hospitalized for COVID-19 during the study period (or who did not die within 30 days of SARS-CoV-2 test).

Demographic and clinical characteristics of patients tested for SARS-CoV-2 were assessed at the time of testing or based on data from the prior two-year period, for characteristics such as comorbidities, Charlson Comorbidity Index and Care Assessment Needs (CAN) score (See *Supplemental Table 1* for full definitions).

Statistical Analyses

For VHA enrollees and for subpopulations, vaccination coverage was reported as the frequency and proportion of individuals with at least one vaccination.

For the TND case-control study, for cases (positive SARS-CoV-2 test) and controls (negative SARS-CoV-2 test), baseline demographic and clinical characteristics of the tested patients were described by reporting frequency and proportion for categorical variables and median interquartile range (IQR) for continuous variables. Missing data were reported. Standardized mean difference (SMD) was used to describe differences in characteristics between cases and controls. We used conditional logistic regression to calculate odds ratios (ORs) with 95% confidence interval (CI) for the association between positive SARS-CoV-2 testing and receipt of mRNA COVID-19 vaccine. VE was calculated as $(1 - \text{OR}_{\text{odds of SARS-CoV-2 in vaccinated vs odds of SARS-CoV-2 in unvaccinated}}) \times 100\%$. Analyses were conducted comparing partial vaccination, days 14-20 after first dose, full vaccination, and late full vaccination (day 14 after second dose and onwards) versus no vaccination. Models for adjusted analyses included covariates for potential confounders of the association between vaccination status and testing positive for SARS-CoV-2. Conditional logistic regression for the case-control analyses of hospitalization and death and for VE against symptomatic disease were conducted similarly.

All analyses were conducted using SAS, version 7.

RESULTS

Vaccination Coverage

By March 7, 2021, 1,547,045 (23.1%) VHA enrollees were administered at least one dose of a COVID-19 vaccine at a VHA facility (Table 1). Vaccination coverage was higher (33.8%) among Veterans ≥ 65 years old. Vaccination coverage for this early vaccination period was 20.6%, 24.9%, and 23.9% for Hispanics, Blacks and Whites, respectively. Vaccination reached homeless Veterans (19.3%), those living in nursing homes (40.9%) (Table 1).

Study Population

We identified 15,404 positive SARS-CoV-2 tests, classified as cases, and 497,584 negative tests, classified as controls (Figure 1). After matching, there were 15,404 cases and 61,610 controls. Baseline characteristics for cases and controls before and after matching are shown in Table 2. At the time of testing, 14,799 (96%) cases and 50,831 (83%) controls were unvaccinated in the matched analysis. Compared with controls, cases were younger and more likely to be White.

Vaccine Effectiveness

Table 3 shows the estimated VE for full and partial vaccination against a documented positive SARS-CoV-2 test, regardless of symptoms. Among the overall population, the adjusted VE for full and partial vaccinations were 94% (95%CI 92-95) and 58% (95%CI 54-62), respectively. VE was similar to that in the overall population for most subpopulations. VE for full vaccination was a few percentage points lower among patients who were overweight/obese (87% (95%CI 82-91)), had cancer (84% (95%CI 73-91)) or had congestive heart disease (85% (95%CI 76-90)).

VE estimates were similar across all age, sex, race, or urban/rural status, with overlapping 95% CIs. For the overall population and all subpopulations, the VE point estimates for partial vaccination defined by occurrence of cases within 14-20 days after the first dose were higher than those for partial vaccination measured starting 7 days after the first dose. When we restricted the analysis to symptomatic cases, VE for the overall population was 91% (95%CI 87-93), about the same as for all tested individuals (Supplemental Table 2).

Effectiveness estimates against hospitalization (89% (95%CI 81-93)), and against death (98.5% (95%CI 86.6-99.8), were similar to the VE we found against infection and symptomatic disease (Tables 3, 4, Supplemental Table 3).

DISCUSSION

The VHA's vaccination effort reached all demographic groups among Veterans in the first three months following availability of mRNA COVID vaccines under EUA. Notably, vaccination coverage was at least as high among Black Veterans as White Veterans.

This nationwide study on COVID-19 mRNA vaccines in the US demonstrated high VE of mRNA vaccines against both laboratory confirmed SARS-CoV-2 infections (regardless of symptoms) and symptomatic disease.[Table 3, *Supplement Table 2*] Although our sample size constrained our ability to analyze subpopulations in the short period we investigated, our VE estimates were similarly high in most subpopulations, for symptomatic cases, and against COVID-19 associated hospitalization and death.

Our VE estimates are comparable to those from the clinical trials (5, 6) and from other observational studies (Table 3, *Supplement Table 2*). Two VE studies from Israel following the rollout of Pfizer-BioNTech COVID-19 Vaccine among individuals ≥ 16 years old found similar results: a national surveillance data study, 95.3% [95%CI 94.9-95.7%](7), and a study in Israel's largest healthcare organization, 92% [95%CI 88-95%](8). Our results were also similar to those from a prospective study among vaccinated healthcare workers in the United Kingdom, 85% [95%CI 74-96%](9), and a smaller study among essential and frontline workers in the US, 90% [95%CI 68-97%](10).

Although power was limited, our VE estimates against COVID-19 hospitalization were comparable to those from two studies in Israel, 97.2% (95%CI 96.8-97.5%) (7) and 87% (95%CI 55-100%)(8), and to a US study of patients ≥ 65 years old, 94% (95%CI 49-99%)(11) (Table 4). Also comparable were our results for VE against death, which was 96.7% (95%CI 96.0-97.3%) in a study in Israel(7) (Table 4).

Our study, using data from a large and diverse U.S. population, adds important context to our understanding of VE because vaccination rollout and SARS-CoV-2 variants have differed from state to state, and country to country. In Israel and the United Kingdom, mRNA COVID-19 vaccine distribution included only the Pfizer-BioNTech COVID-19 Vaccine, and the United Kingdom extended the interval between doses to vaccinate their population more rapidly with one dose, limiting our ability to directly compare with their results(8, 12).

Furthermore, each country has distinct demographic characteristics, so our study allowed for a more in-depth analysis of VE in subpopulations for whom the COVID-19 disease burden has been greater in the U.S., such as Black and Hispanic patients.

Many important prior clinical trials and observational studies (6, 7, 9, 10, 13) had limited sample size to adequately assess the effectiveness of COVID-19 vaccines for people with underlying medical conditions, even though some conditions may predispose individuals to severe consequences from infection(14). The immune response to vaccination among immunocompromised individuals has not been fully explored. We found that, when fully vaccinated, effectiveness is 88% (95%CI, 82-92) for immunocompromised patients, which is reassuring. Further evaluation of these patients by underlying disease and treatment is warranted given the response to infection may vary accordingly (14). Lee et al.(15) demonstrated COVID-19 outcomes may be more severe among patients with hematological malignancies versus solid tumors. As multiple studies, including ours, have shown (5, 9, 10, 12, 13), the mRNA vaccines show some effectiveness even after just the first dose (Tables 3, 4, Supplement Table 2).

COVID-19 has disproportionately affected racial and ethnic minorities and low-income communities (16-18). Our results show the VHA was able to vaccinate minority and low-income Veterans with similar efficiency. The rates of SARS-CoV-2 testing in the first half of 2020 were higher among racial and ethnic minorities than among Whites. Prior to vaccination, African American and Hispanic Veterans were at 30 to 40% higher risk of infection compared to their Caucasian counterparts(17). After VHA's thorough effort to provide vaccination to all Veterans, regardless of racial/ethnic group or socio-economic status, we found that the risk of SARS-CoV-2 infection (irrespective of symptoms) following full vaccination was reduced for all, with similar VE for all racial and ethnic groups, demonstrating that the equitable distribution of vaccination is an effective means to reduce racial and socio-economic disparity in COVID-19 disease burden.

STRENGTHS AND LIMITATIONS

A main concern regarding test-negative studies is misclassification. Our study relied on records of vaccination collected prospectively and in near real-time rather than subjects' recall. While this study demonstrated that


vaccination coverage reached all demographic subgroups, the coverage rates reported here may be conservative estimates (19), given that vaccination of individuals by State and local health departments might have not been reported to the VHA. Moreover, by the end of 2020, VHA had standardized its testing and case definitions, unlike at the beginning of the pandemic(20). We used SARS-CoV-2–positive test results coupled with COVID-19 symptoms in a sensitivity analysis to reduce potential misclassification and found that VE matched that of the main analysis at 91% (95%CI 87, 93) (*Supplemental Table 3*). Some Veterans vaccinated through the VHA could have been hospitalized in a non-VHA facility, especially in rural communities (21). We limited the study population to those who routinely sought care at VHA facilities to minimize the likelihood of including patients who were vaccinated or sought treatment for COVID-19 elsewhere. To further address this, we utilized available Medicare data and repeated the analysis including any records of vaccination and hospitalization outside the VHA for these patients. The results were similar with a VE of 87% (95% CI 83, 89) (*Supplemental Table 4*). We also considered that our analysis utilized data from both antigen and PCR tests, and there may be differences in the sensitivities and specificities between tests which could lead to misclassification of cases and controls. We determined that 94% of tests were PCR and 6% were antigen tests. While this misclassification would likely be non-differential, and we repeated the analysis of VE against infection, stratifying by type of test and found no effect on the estimate (*Supplemental Table 6*). Our analysis included test results from all adult patients, without imposing strict rules to identify vaccine eligibility at the time of their test because the prevalence of conditions which would have made patients vaccine eligible early on was quite high (e.g., 55% hypertension among controls); we also conducted analyses for subgroups of patients who would have been vaccine eligible early on. Nevertheless, there could still be residual misclassification and differences in health seeking behavior and disease risk between different subpopulations and for individuals in the VHA and CMS system that would require further investigation in future studies.

CONCLUSION

Over a period of only three months after the first COVID-19 vaccine was authorized, the VHA successfully vaccinated and tested millions of Veterans of all socio-economic groups for COVID-19. We found mRNA

vaccines to be highly effective against the risk of SARS-CoV-2 laboratory-confirmed infection, symptomatic disease, hospitalization, and death. The effectiveness of these vaccines, combined with their equitable and efficient deployment, have resulted in attenuated COVID-19 disease burden among all VHA enrolled Veterans and specific vulnerable populations.

Figure 1. SARS-CoV-2 PCR and antigen tests (December 14, 2020-March 7, 2021) meeting study criteria






Table 1. COVID-19 Vaccination Coverage through March 7, 2021 among VHA Enrollees^a

	Number of enrollees [A]	Vaccinated enrollees [B]	% Vaccination coverage [B/A]
All enrollees	6,710,750	1,547,045	23%
Age range, y			
18-44	1,382,988	63,794	5%
45-64	1,950,293	340,959	18%
65-74	1,895,735	625,177	33%
75-84	1,000,503	367,395	37%
≥85	481,231	149,720	31%
≥65	3,377,469	1,142,292	34%
Sex			
Female	634,302	95,579	15%
Male	6,076,448	1,451,466	24%
Race or ethnic group			
Black	1,110,223	276,750	25%
Hispanic	464,284	95,845	21%
White	4,407,279	1,051,749	24%
Other	384,981	80,993	21%
Missing	343,983	41,708	12%
Urban-rural classification			
Highly rural	83,386	13,649	16%
Rural	2,176,409	437,793	20%
Urban	4,450,955	1,095,603	25%
VHA defined priority group			
1-4	2,545,311	552,638	22%
5-6	2,156,949	475,988	22%
7-8	2,008,490	518,419	26%
Nursing home resident	32,063	13,103	41%
Homeless	124,850	24,103	19%
Low Income	663,649	138,463	21%
Comorbidities			
Asthma	336,849	135,672	40%
Cancer	191,185	91,660	48%
Cancer, metastatic	20,768	10,520	51%
Coronary artery disease	367,556	161,922	44%
Congestive heart failure	166,994	76,177	46%
Chronic heart disease	212,324	97,836	46%
Chronic obstructive pulmonary disease	363,203	146,639	40%
Cardiovascular disease	114,495	48,279	42%
Dementia	72,101	26,014	36%
Dyslipidemia	745,217	289,270	39%
Human immunodeficiency virus (HIV)	19,422	7,758	40%
Hypertension	1,473,558	572,278	39%
Liver disease, mild	94,328	36,314	38%

Liver disease, severe	8,066	3,336	41%
Myocardial infarction	36,544	16,591	45%
Hemiplegia or paraplegia	19,979	9,048	45%
Peptic ulcer disease	8,683	3,761	43%
Peripheral vascular disease	140,128	65,357	47%
Rheumatoid arthritis	43,543	17,674	41%
Renal disease	219,051	100,879	46%
Immunocompromised	455,601	206,098	45%
Diabetes mellitus	967,034	384,596	40%

^aDefinitions for urban-rural classification, VHA defined priority group, and comorbidities are provided in Supplemental Table 1.

Table 2. Exposure Status and Baseline Characteristics of Study Participants^a

	Unmatched			Matched		
	Cases (n=15,404)	Controls (n=497,584)	SMD ^b	Cases (n=15,404)	Controls (n=61,610)	SMD ^b
Vaccination status, No. (%)						
Full	72 (1)	34,979 (7)	35	72 (1)	4,959 (8)	38
Partial	533 (4)	36,545 (7)	17	533 (4)	5,820 (9)	25
None	14,799 (96)	426,060 (86)	37	14,799 (96)	50,831 (83)	45
Vaccine manufacturer, No. (%)						
Moderna	342 (2)	39,007 (8)	26	342 (2)	6,182 (10)	33
Pfizer-BioNTech	263 (2)	32,517 (7)	24	263 (2)	4,597 (8)	28
None (unvaccinated)	14,799 (96)	426,060 (86)	37	14,799 (96)	50,831 (83)	45
Month of Test, No. (%)						
2020-Dec.	4,603 (30)	111,052 (22)	17	4,603 (30)	18,349 (30)	0
2021-Jan.	7,306 (47)	190,353 (38)	18	7,306 (47)	25,504 (41)	12
2021-Feb.	2,962 (19)	155,601 (31)	28	2,962 (19)	14,537 (24)	11
2021-Mar.	533 (4)	40,578 (8)	20	533 (4)	3,220 (5)	9
Care setting for test, No. (%)						
ED/At Admission	6,959 (45)	119,201 (24)	46	6,959 (45)	15,982 (26)	41
Outpatient	8,445 (55)	378,383 (76)	46	8,445 (55)	45,629 (74)	41
Age, years						
18-44	2,535 (17)	73,236 (15)	5	2,535 (17)	668 (1)	56
45-64	5,409 (35)	177,629 (36)	1	5,409 (35)	22,642 (37)	3
65-74	4,757 (31)	160,157 (32)	3	4,757 (31)	24,673 (40)	19
75-84	1,928 (13)	64,096 (13)	1	1,928 (13)	9,481 (15)	8
85+	775 (5)	22,466 (5)	2	775 (5)	4,147 (7)	7
Sex, No. (%)						
Female	1,457 (10)	55,591 (11)	6	1,457 (10)	5,868 (10)	0
Male	13,947 (91)	441,993 (89)	6	13,947 (91)	55,742 (91)	0
Race, No. (%)						
Black	3,848 (25)	121,718 (25)	1	3,848 (25)	19,807 (32)	16
Hispanic	1,014 (7)	34,816 (7)	2	1,014 (7)	2,884 (5)	8
White	9,620 (63)	303,234 (61)	3	9,620 (63)	34,731 (56)	12
Other	922 (6)	37,816 (8)	6	922 (6)	4,188 (7)	3
Rurality, No. (%)						
Highly rural	107 (1)	3,015 (1)	1	107 (1)	376 (1)	1
Rural	4,667 (30)	120,555 (24)	14	4,667 (30)	14,758 (24)	14
Urban	10,630 (69)	374,014 (75)	14	10,630 (69)	46,476 (75)	14
HHS region, No. (%)						
Region 1	803 (5)	23,289 (5)	2	803 (5)	3,212 (5)	0
Region 2	763 (5)	23,723 (5)	1	763 (5)	3,052 (5)	0
Region 3	2,286 (15)	48,958 (10)	15	2,286 (15)	9,143 (15)	0
Region 4	3,944 (26)	138,087 (28)	4	3,944 (26)	15,976 (26)	0
Region 5	1,661 (11)	67,333 (14)	8	1,661 (11)	6,644 (11)	0
Region 6	3,425 (22)	58,556 (12)	28	3,425 (22)	13,696 (22)	0
Region 7	714 (5)	23,441 (5)	0	714 (5)	2,856 (5)	0
Region 8	445 (3)	15,880 (3)	2	445 (3)	1,780 (3)	0
Region 9	976 (6)	80,345 (16)	31	976 (6)	3,904 (6)	0
Region 10	337 (2)	17,946 (4)	8	337 (2)	1,348 (2)	0
Homeless, No. (%)	620 (4)	32,933 (7)	12	620 (4)	4,646 (8)	15
Low income, No. (%)	2,139 (14)	77,418 (16)	5	2,139 (14)	12,059 (20)	15

Nursing home use, No. (%)	124 (1)	9,212 (2)	9	124 (1)	2,021 (3)	18
VA priority group, No. (%)						
1-4	5,823 (38)	210,310 (42)	9	5,823 (38)	32,276 (52)	29
5-6	5,131 (33)	161,290 (32)	2	5,131 (33)	17,182 (28)	12
7-8	4,450 (29)	125,984 (25)	8	4,450 (29)	12,152 (20)	22
Quan's CCI						
Median (IQR)	0 (0, 2)	1 (0, 2)		0 (0, 2)	1 (0, 3)	
BMI, No. (%)						
Overweight/ obese	7,654 (50)	226,955 (46)	8	7,654 (50)	26,933 (44)	12
Comorbidities						
Asthma	1,726 (11)	68,761 (14)	8	1,726 (11)	11,803 (19)	22
Cancer	992 (6)	40,710 (8)	7	992 (6)	5,923 (10)	12
Cancer (metastatic)	148 (1)	7,718 (2)	5	148 (1)	1,181 (2)	8
Coronary artery disease	2,018 (13)	68,512 (14)	2	2,018 (13)	11,050 (18)	13
Congestive heart failure	1,208 (8)	45,941 (9)	5	1,208 (8)	7,857 (13)	16
Chronic kidney disease	1,458 (10)	50,718 (10)	2	1,458 (10)	8,585 (14)	14
Chronic obstructive pulmonary disease	1,866 (12)	74,799 (15)	9	1,866 (12)	12,812 (21)	24
Cardiovascular disease	676 (4)	30,431 (6)	8	676 (4)	5,464 (9)	18
Dementia	489 (3)	30,981 (6)	14	489 (3)	6,619 (11)	30
Diabetes mellitus (complicated)	1,827 (12)	58,907 (12)	0	1,827 (12)	10,107 (16)	13
Diabetes mellitus (uncomplicated)	2,830 (18)	77,950 (16)	7	2,830 (18)	11,647 (19)	1
Dyslipidemia	3,574 (23)	122,001 (25)	3	3,574 (23)	18,732 (30)	16
HIV	82 (1)	4,069 (1)	3	82 (1)	923 (2)	10
Hypertension	6,694 (44)	217,124 (44)	0	6,694 (44)	33,962 (55)	23
Liver disease (mild)	578 (4)	24,199 (5)	5	578 (4)	4,098 (7)	13
Liver disease (moderate/severe)	78 (1)	3,781 (1)	3	78 (1)	584 (1)	5
Myocardial infarction (history)	334 (2)	13,182 (3)	3	334 (2)	2,122 (3)	8
Peripheral vascular disease	889 (6)	37,031 (7)	7	889 (6)	6,342 (10)	17
Rheumatoid arthritis	218 (1)	7,181 (1)	0	218 (1)	1,117 (2)	3
Renal disease	1,491 (10)	51,562 (10)	2	1,491 (10)	8,706 (14)	14
Atrial fibrillation	1,205 (8)	42,972 (9)	3	1,205 (8)	6,621 (11)	10
Arthritis	1,368 (9)	48,622 (10)	3	1,368 (9)	8,294 (14)	15
Bronchiectasis	19 (0)	947 (0)	2	19 (0)	154 (0)	3
Depression	2,254 (15)	86,456 (17)	7	2,254 (15)	12,162 (20)	14
Embolism (history)	304 (2)	12,795 (3)	4	304 (2)	2,164 (4)	9
Falls (history)	114 (1)	6,726 (1)	6	114 (1)	1,163 (2)	10
Hepatitis B	28 (0)	702 (0)	1	28 (0)	158 (0)	2
Hepatitis C	88 (1)	3,995 (1)	3	88 (1)	880 (1)	9
Hyperlipidemia	4,628 (30)	151,284 (30)	1	4,628 (30)	23,000 (37)	15
Interstitial lung disease	118 (1)	5,790 (1)	4	118 (1)	965 (2)	7
Impaired mobility	39 (0)	4,903 (1)	9	39 (0)	1,026 (2)	15

Musculoskeletal disorder	7,390 (48)	255,372 (51)	7	7,390 (48)	36,063 (59)	21
Mycoses	777 (5)	37,023 (7)	10	777 (5)	6,979 (11)	23
Obesity	1,710 (11)	54,124 (11)	1	1,710 (11)	7,355 (12)	3
Parkinson's	117 (1)	7,521 (1)	7	117 (1)	1,244 (2)	11
Sickle cell disease	11 (0)	387 (0)	0	11 (0)	87 (0)	2
Solid organ transplant recipient	69 (0)	2,756 (1)	2	69 (0)	422 (1)	3
Stroke / transient ischemic attack	339 (2)	16,671 (3)	7	339 (2)	3,041 (5)	15
Urinary tract infection	371 (2)	19,079 (4)	8	371 (2)	3,594 (6)	17
Immunocompromised	2,324 (15)	96,783 (20)	12	2,324 (15)	14,719 (24)	22
CAN Score, Mean (SD)						
Mortality-1 year	5.2% (10)	5.7% (11)	5	5.2% (10)	7.6% (12%)	22
Mortality-90 days	1.5% (4)	1.7% (4)	4	1.5% (4)	2.3% (5%)	17
Event-1 year	20.5% (20)	20.6% (21)	1	20.5% (20)	24.1% (23%)	16
Event-90 days	8.0% (11)	8.3% (12)	3	8.0% (11)	10.1% (14%)	17
Hospitalization-1 year	17.8% (18)	18.6% (19)	4	17.8% (18)	21.6% (21%)	19
Hospitalization-90 days	7.2% (10)	7.8% (11)	6	7.2% (10)	9.5% (13%)	20
Any COVID-19 symptoms	10,499 (68)	105,464 (21)	107	10,499 (68)	13,067 (21)	107
Influenza vaccination (2019/20 season)	135 (1)	4,521 (1)	0	135 (1)	753 (1)	3
Influenza vaccination (2020/21 season)	1,570 (10)	54,432 (11)	2	1,570 (10)	8,506 (14)	11

Abbreviations: BMI, body mass index; CAN Score, Care Assessment Needs score; No., number; SMD, standardized mean difference; VA, Veterans Affairs.

^aDefinitions for variables are provided in Supplemental Table 1.

^bSMD of 10 or greater was used to identify imbalance between cases and controls.

Table 3. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection^a

	VE, % (95% CI)			
	Full vs. no vaccination		Partial vs. no vaccination	
	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
Overall	96 (95, 97)	94 (92, 95)	70 (67%, 73%)	58 (54, 62)
Age, y				
18-64	91 (84, 95)	91 (83, 95)	59 (49, 67)	52 (40, 62)
≥65	92 (90, 94)	92 (89, 94)	57 (52, 61)	54 (48, 58)
18-79	91 (88, 93)	91 (88, 93)	55 (50, 59)	53 (48, 58)
≥80	93 (89, 96)	93 (88, 96)	59 (50, 66)	56 (46, 64)
VHA defined priority group				
1-4	93 (90, 95)	93 (89, 95)	60 (53, 65)	56 (49, 63)
5-6	88 (83, 92)	90 (85, 93)	53 (45, 60)	55 (46, 62)
7-8	90 (84, 94)	90 (84, 94)	43 (33, 52)	47 (37, 56)
Race or ethnic group				
Black	94 (89, 97)	93 (88, 96)	49 (39, 58)	48 (37, 57)
Hispanic	82 (59, 92)	73 (38, 89)	52 (25, 69)	44 (13, 65)
White	91 (88, 93)	90 (87, 93)	56 (51, 61)	55 (50, 60)
Other	98 (86, 100)	98 (86, 100)	61 (40, 75)	65 (46, 78)
Sex				
Female	86 (62, 95)	82 (51, 94)	73 (50, 85)	65 (35, 81)
Male	92 (90, 94)	92 (90, 94)	54 (49, 58)	54 (50, 58)
Urban-rural				
Rural	93 (89, 96)	93 (89, 96)	60 (52, 66)	58 (50, 65)
Urban	91 (88, 93)	90 (87, 93)	52 (47, 57)	50 (44, 55)
Income				
Low income	92 (83, 96)	92 (84, 96)	58 (45, 68)	56 (42, 66)
Homeless				
Homeless	93 (78, 98)	93 (79, 98)	60 (36, 76)	56 (28, 73)
BMI				
Overweight/Obese	88 (83, 92)	87 (82, 91)	48 (41, 55)	45 (37, 52)
Underlying medical conditions				
Cancer	85 (74, 91)	84 (73, 91)	45 (28, 58)	43 (25, 56)
Congestive heart failure	87 (80, 92)	85 (76, 90)	57 (46, 66)	54 (42, 64)
Chronic kidney disease	93 (87, 96)	91 (85, 94)	54 (43, 63)	56 (45, 64)
Diabetes mellitus	93 (90, 95)	92 (88, 94)	59 (53, 65)	56 (49, 62)
Hypertension	91 (88, 93)	91 (88, 93)	56 (50, 61)	56 (51, 61)
Immunocompromised	86 (79, 90)	88 (82, 92)	42 (31, 52)	43 (32, 52)
Adjusted VE, % (95% CI) [reference group: unvaccinated]				
	Late full vaccination (from 14 days after dose 2)	Full vaccination (from 7 days after dose 2)	14 to 20 days after dose 1	Partial vaccination (7 days after dose 1 until dose 2)
Overall				
	95 (3, 96)	94 (92, 95)	63 (57, 69)	58 (54, 62)
BMI				
Overweight/Obese	91 (85, 95)	87 (82, 91)	58 (46, 67)	45 (37, 52)
Underlying medical conditions				

Cancer	86 (73, 93)	84 (73, 91)	56 (29, 73)	43 (25, 56)
Congestive heart failure	88 (79, 94)	85 (76, 90)	70 (53, 81)	54 (42, 64)
Chronic kidney disease	92 (84, 95)	91 (85, 94)	66 (49, 78)	55 (45, 64)
Diabetes mellitus	93 (88, 95)	92 (88, 94)	64 (53, 72)	56 (49, 62)
Hypertension	92 (89, 95)	91 (88, 93)	62 (53, 69)	56 (51, 61)
Immunocompromised	86 (78, 91)	88 (82, 92)	57 (41, 68)	43 (32, 52)

Abbreviations: BMI, body mass index; VE, vaccine effectiveness; VHA, Veterans Health Affairs.

^aSee Supplemental Table 1 for definitions of variables in this table.

^bThe adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.

Table 4. Vaccine Effectiveness Against COVID-19-related Hospitalization and Death^a


VE against COVID-19-related hospitalization, % (95% CI)					
		Full vs. no vaccination		Partial vs. no vaccination	
		Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
Overall		87 (78, 92)	89 (81, 93)	31 (17, 43)	40 (27, 50)
VE against COVID-19-related death, % (95% CI)					
		Full vs. no vaccination		Partial vs. no vaccination	
		Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
Overall		95 (64, 99)	99 (87, 100)	37 (2, 60)	55 (21, 74)

Abbreviations: BMI, body mass index; VE, vaccine effectiveness; VHA, Veterans Health Affairs.

^aSee Supplemental Table 1 for definitions of variables in this table.

^bThe adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.

Supplementary Material



Supplemental Figure 1. Vaccination exposure classification

Supplemental Table 1. Definitions of variables

Variable	Values	Definition	Timing
Age	Integer	Age as of the specimen collection date for SARS-CoV-2 lab test	Table 1: Determined at March 7, 2021; Table 2: Determined at the specimen collection date for SARS-CoV-2 lab test during the study period (December 14, 2020 to March 7, 2021)
Sex	Female/male	As defined in VHA data	Most recent available
Race	Black Hispanic White Other	Black: non-Hispanic black Hispanic: Hispanic any race White: non-Hispanic white Other: non-Hispanic other race, missing race, declined to state, unknown	Most recent available
Rurality	Highly Rural Rural Urban	VHA defined based on the Rural-Urban Community Area (RUCA) system [https://www.ruralhealth.va.gov/rural-definition.asp]	Most recent available
VHA defined priority group	1, 2, 3, 4, 5, 6, 7, 8	VA defined based on factors including military service history, disability rating and income level to identify Veterans to determine enrolment priority; 1 is the highest priority [https://www.va.gov/health-care/eligibility/priority-groups/]	Most recent available
Nursing home use	0/1	1 = Any nursing home or long-term care indicated on an inpatient admission or place of disposition	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
Health and Human Services (HHS) region	Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Region 7 Region 8 Region 9 Region 10	Region 1: (state abbreviation) CT, ME, NH, RI, VT Region 2: NJ, NY Region 3: DE, DC, MD, PA, VA, WV Region 4: AL, FL, GA, KY, MS, NC, SC, TN Region 5: IL, IN, MI, MN, OH, WI Region 6: AR, LA, NM, OK, TX Region 7: IA, KS, MO, NE Region 8: CO, MT, ND, SD, UT, WY Region 9: AZ, CA, HI, NV Region 10: AK, ID, OR, WA	Most recent available value based on location of patient's residence
Homeless	0/1	1= ICD-10 code Z59.0 or Z59.1 on any inpatient or outpatient	During 2 years prior to specimen collection date for SARS-CoV-2 lab test

		record	
Low Income	0/1	1 = income less than 12,760, but not missing income 0 = missing or income greater than equal to 12760	During 2 years prior to specimen collection date for SARS-CoV-2 lab test
Quan-CCI	Numeric	Using ICD-10 codes from any inpatient or outpatient record, computed Charlson Comorbidity Index, Quan's version [Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005; 43(11):1130-1139. DOI: 10.1097/01.mlr.0000182534.19832.83]	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
BMI	Normal Overweight/obese Missing	Normal: BMI less than 26 Overweight/obese: BMI greater than or equal to 26	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
Comorbidities		All comorbidities listed below have 1 inpatient or 2 outpatient records with the corresponding ICD-10 code	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
Asthma	0/1	ICD-10 code J45* ICD-10 code J44.9* ICD-10 code J67.8*	
Cancer	0/1	Charlson condition definitions using ICD-10 codes	
Cancer metastatic	0/1	Charlson condition definitions using ICD-10 codes	
Coronary artery disease	0/1	ICD-10 code I 25*	
Congestive heart failure	0/1	Charlson condition definitions using ICD-10 codes	
Chronic kidney disease	0/1	ICD-10 code N18*	
Chronic obstructive pulmonary disease	0/1	Charlson condition definitions using ICD-10 codes	
Cardiovascular disease	0/1	Charlson condition definitions using ICD-10 codes	
Dementia	0/1	Charlson condition definitions using ICD-10 codes	
Diabetes mellitus with complications	0/1	Charlson condition definitions using ICD-10 codes	
Diabetes mellitus without complications	0/1	Charlson condition definitions using ICD-10 codes	
Dyslipidemia	0/1	ICD-10 code E78.5*	
HIV	0/1	Charlson condition definitions using ICD-10 codes	
Hypertension	0/1	ICD-10 code H35.03 ICD-10 code I10*	

		ICD-10 code I11* ICD-10 code I12* ICD-10 code I13* ICD-10 code I15* ICD-10 code I16 ICD-10 code I67.4	
Liver disease, mild	0/1	Charlson condition definitions using ICD-10 codes	
Liver disease, severe	0/1	Charlson condition definitions using ICD-10 codes	
Myocardial infarction (history)	0/1	Charlson condition definitions using ICD-10 codes	
Para/hemiplegia	0/1	Charlson condition definitions using ICD-10 codes	
Peptic ulcer disease	0/1	Charlson condition definitions using ICD-10 codes	
Peripheral vascular disease	0/1	Charlson condition definitions using ICD-10 codes	
Rheumatoid arthritis	0/1	Charlson condition definitions using ICD-10 codes	
Renal disease	0/1	Charlson condition definitions using ICD-10 codes	
Atrial fibrillation	0/1	ICD-10 code I48.0 ICD-10 code I48.11 ICD-10 code I48.19 ICD-10 code I48.21 ICD-10 code I48.91	
Anaphylaxis (history)	0/1	ICD-10 code Z87.892	
Arthritis	0/1	ICD-10 code M15* through M19*	
Bleeding diathesis	0/1	ICD-10 code D69.9	
Bronchiectasis	0/1	ICD-10 code J47*	
Depression	0/1	ICD-10 code F33*	
Down Syndrome	0/1	ICD-10 code Q90*	
Embolism (history)	0/1	ICD-10 code I82* ICD-10 code I74* ICD-10 code I26*	
Falls (history)	0/1	ICD-10 code W19*	
Gout	0/1	ICD-10 code M1A*	
Hepatitis B	0/1	ICD-10 code B19.1*	
Hepatitis C	0/1	ICD-10 code B19.2*	
Hyperlipidemia	0/1	ICD-10 code E78.2 ICD-10 code E78.41 ICD-10 code E78.49 ICD-10 code E78.5	
Hypersensitivity pneumonitis	0/1	ICD-10 code J67*	

Interstitial lung disease	0/1	ICD-10 code J80* ICD-10 code J81* ICD-10 code J82* ICD-10 code J84*	
Impaired mobility	0/1	ICD-10 code Z74.01 ICD-10 code Z74.09	
Musculoskeletal disorder	0/1	ICD-10 code M00* through M99*	
Mycoses	0/1	ICD-10 code B35* through B49*	
Obesity	0/1	ICD-10 code E66*	
Paranoia	0/1	ICD-10 code F22* ICD-10 code F60*	
Parkinson's	0/1	ICD-10 code G20*	
Pregnancy (history)	0/1	ICD-10 code Z33*	
Drug-induced anaphylaxis	0/1	ICD-10 code Z88*	
Sickle cell disease	0/1	ICD-10 code D57*	
Solid organ transplant recipient	0/1	ICD-10 code Z94*	
Stroke / transient ischemic attack	0/1	ICD-10 code I63* ICD-10 code G45*	
Urinary tract infection	0/1	ICD-10 code N39.0	
Immunocompromised	0/1	ICD-10 code B20* ICD-10 code B59* ICD-10 code B97.3* ICD-10 code D47.Z1* ICD-10 code D70* ICD-10 code D71* ICD-10 code D72* ICD-10 code D73* ICD-10 code D76* ICD-10 code D80* ICD-10 code D81* ICD-10 code D82* ICD-10 code D83* ICD-10 code D84* ICD-10 code D89* ICD-10 code M05* ICD-10 code M06* ICD-10 code M07* ICD-10 code M08* ICD-10 code M30* ICD-10 code M31* ICD-10 code M32* ICD-10 code M33* ICD-10 code M34* ICD-10 code M35.0* ICD-10 code M35.9* ICD-10 code Q89.0* ICD-10 code T45.1X1	

		ICD-10 code Z21* ICD-10 code Z48.2* ICD-10 code Z51.0* ICD-10 code Z51.1* ICD-10 code Z94*	
Hematological malignancy	0/1	ICD-10 codes 81.70, 81.79, 81.90 ICD-10 codes 82.90 ICD-10 codes 84.10, 84.40 85.80 ICD-10 code C88.0 ICD-10 code C90.00 ICD-10 codes C91.00, 91.01, 91.10, 91.11, 91.40 ICD-10 codes C92.00, 92.01, 92.10, 92.11, 92.30 96.2 ICD-10 code D47.2	
Vaccination status	None Partial Full	None: until first vaccination date Partial: from 7 days after the first vaccination date and before the second vaccination date Full: from 7 days after the second vaccination date	Determined at the specimen collection date for SARS-CoV-2 lab test during the study period (December 14, 2020 to March 7, 2021)
Vaccine manufacturer	None Moderna Pfizer	None: no vaccination recorded Moderna: CPT codes 91301, 0011A, 0012A or vaccination name Pfizer: CPT codes 91300, 0001A, 0002A or vaccination name	Determined at date of first vaccination during the study period (December 14, 2020 to March 7, 2021)
Month of SARS-CoV-2 test	2020-Dec 2021-Jan 2021-Feb 2021-Mar	Month of the specimen collection date for SARS-CoV-2 lab test	Study period (December 14, 2020 to March 7, 2021)
Care setting for SARS-CoV-2 test	ED/At Admission Outpatient	ED/At Admission: Specimen collection date for SARS-CoV-2 lab test on the same date as ED visit or during an inpatient stay Outpatient: Specimen collection date for SARS-CoV-2 lab test on the same date as outpatient or urgent care visit	Assessed from specimen collection dates and visit dates during the study period (December 14, 2020 to March 7, 2021)
Health and Human Services (HHS) region	Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Region 7 Region 8 Region 9 Region 10	Region 1: (state abbreviation) CT, ME, NH, RI, VT Region 2: NJ, NY Region 3: DE, DC, MD, PA, VA, WV Region 4: AL, FL, GA, KY, MS, NC, SC, TN Region 5: IL, IN, MI, MN, OH, WI Region 6: AR, LA, NM, OK,	Most recent available value based on location of patient residency

		TX Region 7: IA, KS, MO, NE Region 8: CO, MT, ND, SD, UT, WY Region 9: AZ, CA, HI, NV Region 10: AK, ID, OR, WA	
Homeless	0/1	1= ICD-10 code Z59.0 or Z59.1 on any inpatient or outpatient record	During 2 years prior to specimen collection date for SARS-CoV-2 lab test
Low income	0/1	1 = income less than 12,760, but not missing income 0 = missing or income greater than equal to 12760	During 2 years prior to specimen collection date for SARS-CoV-2 lab test
Quan-CCI	Numeric	Using ICD-10 codes from any inpatient or outpatient record, computed Charlson Comorbidity Index, Quan's version [REF Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD- 9-CM and ICD-10 administrative data. Medical Care 2005; 43(11):1130-1139. DOI: 10.1097/01.mlr.0000182534.19 832.83]	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
BMI	Normal Overweight/ obese Missing	Normal: BMI less than 26 Overweight/obese: BMI greater than or equal to 26	During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
CAN Score		Score to identify patients at highest risk of hospitalization and mortality. As indicated in VHA data. If missing, the score is assumed to be zero.[https://www.va.gov/HEALTHCAREEXCELLENCE/about/organization/examples/care-assessment-needs.asp]	Most recent CAN score during 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test
Mortality-1 year	Percentage of probability	Measurement of risk of mortality in next year	
Mortality-90 days	Percentage of probability	Measurement of risk of mortality in the next 90 days	
Event-1 year	Percentage of probability	Measurement of risk of any visit or event in the next year	
Event-90 days	Percentage of probability	Measurement of risk of any visit or event in the next 90 days	
Hospitalization-1 year	Percentage of probability	Measurement of risk of a hospitalization in the next year	
Hospitalization-90 days	Percentage of probability	Measurement of risk of a hospitalization in the next 90 days	

COVID-19 symptoms		Symptoms as indicated from a combination of text search on inpatient admissions, ICD-10 codes, or as indicated in the COVID Domain	+/- 14 days around and including the COVID-19 lab test specimen date.
Any	0/1	Any one of the listed symptoms	
None	0/1	Missing all of the listed symptoms	
Fever	0/1	ICD-10 code R50.9* COVID domain variable fever30d	
Shortness of breath	0/1	ICD-10 code R06.02* ICD-10 code R06.0* ICD-10 code R09.02* COVID domain variable dyspnea30d	
Cough	0/1	ICD-10 code R05* COVID domain variable cough30d	
Loss of taste/smell	0/1	ICD-10 code R43.9* ICD-10 code R43.8* ICD-10 code R43.1* ICD-10 code R43* COVID domain variable lossoftaste30d	
Chills	0/1	ICD-10 code R68.83* ICD-10 code R68.89* COVID domain variable chills30d	
Diarrhea	0/1	ICD-10 code R19.7* COVID domain variable diarrhea30d	
Sore throat	0/1	ICD-10 code J02.8* ICD-10 code J02.9* COVID domain variable sorethroat30d	
Myalgia	0/1	ICD-10 code M79.1* COVID domain variable myalgia30d	
Vaccination (other pathogens)		Other pathogen vaccinations identified by text search or CPT code (listed below)	The year prior to the specimen collection date for SARS-CoV-2 lab test
Influenza (2019/20 season)	0/1	CPT Code between 90655 and 90659, Q2034 and Q2039 CPT Code 90662	
Influenza (2020/21 season)	0/1	CPT Code between 90655 and 90659, Q2034 and Q2039 CPT Code 90662	
Abbreviations: BMI, body mass index; CAN Score, care assessment needs score; CPT, Current Procedural Terminology; ED, emergency department; HHS, Health and Human Services; International Classification of Diseases 10th Revision; VHA, Veterans Health Administration.			

Supplemental Table 2. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection Among Patients with COVID-19 Symptoms^a

	VE, % (95%CI)			
	Full vs. no vaccination		Partial vs. no vaccination	
	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
Overall	93 (90, 95)	91 (87, 93)	52 (46, 57)	43 (36, 50)
Age, years				
18-64	90 (77, 96)	89 (73, 95)	40 (22, 54)	31 (10, 48)
≥65	89 (84, 92)	88 (83, 91)	43 (35, 49)	42 (33, 49)
18-79	90 (85, 93)	89 (85, 93)	42 (33, 49)	40 (31, 47)
≥80	88 (77, 93)	88 (79, 94)	44 (29, 56)	38 (21, 52)
VHA defined priority group				
1-4	91 (85, 95)	93 (87, 96)	43 (31, 52)	45 (34, 55)
5-6	86 (76, 92)	86 (77, 92)	45 (33, 55)	44 (31, 55)
7-8	83 (70, 90)	86 (76, 92)	34 (18, 46)	32 (16, 45)
Race or ethnic group				
Black	94 (85, 97)	94 (85, 98)	31 (13, 45)	31 (13, 45)
Hispanic	93 (52, 99)	94 (54, 99)	29 (-21, 58)	16 (-44, 52)
White	87 (81, 91)	86 (80, 90)	48 (40, 55)	43 (34, 51)
Other	96 (68, 99)	93 (49, 99)	47 (12, 68)	37 (-6, 63)
Sex				
Female	77 (25, 93)	68 (-6, 90)	59 (21, 79)	41 (-16, 70)
Male	90 (86, 93)	88 (84, 92)	42 (35, 48)	42 (35, 48)
Urban-rural				
Rural	88 (78, 94)	87 (77, 93)	46 (34, 57)	41 (26, 53)
Urban	90 (86, 93)	89 (84, 92)	40 (31, 48)	41 (32, 49)
BMI				
Overweight/Obese	82 (66, 90)	83 (68, 91)	31 (9, 47)	39 (20, 54)
Underlying medical conditions				
Cancer	79 (58, 89)	77 (56, 88)	37 (13, 55)	37 (11, 55)
Congestive heart failure	77 (60, 87)	76 (58, 87)	43 (24, 57)	42 (23, 57)
Chronic kidney disease	88 (79, 94)	88 (78, 94)	40 (23, 53)	43 (27, 56)
Diabetes mellitus	91 (86, 95)	92 (86, 95)	47 (37, 55)	45 (34, 54)
Hypertension	88 (83, 92)	87 (82, 91)	47 (38, 54)	42 (32, 50)
Immuno-compromised	82 (71, 88)	83 (72, 89)	28 (11, 42)	34 (18, 47)
Abbreviations: BMI, body mass index; VE, vaccine effectiveness.				
^a See Supplemental Table 1 for definitions of variables in this table.				
^b The adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.				

Supplemental Table 3. Vaccination Status for Cases and Controls in Analysis of Vaccine Effectiveness Against COVID-19-related Hospitalization and Death

COVID-19-related hospitalization				
	Unmatched		Matched	
	Cases (n=3,209)	Controls (n=316,895)	Cases (n=3,209)	Controls (n=13,075)
COVID-19 vaccination status				
Full	17	11,656	17	442
Partial	151	18,901	151	843
None	3,041	286,338	3,041	11,790
COVID-19-related death				
	Unmatched		Matched	
	Cases (n=669)	Controls (n=316,895)	Cases (n=669)	Controls (n=2,728)
COVID-19 vaccination status				
Vaccinated*	25	30,557	25	215
None	644	286,338	644	2,513
*A breakdown by full and partial vaccination status would violate federal cell size suppression policy				

Supplemental Table 4. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection, Combining VA and CMS Data^{a,b}

	VE, % (95%CI)			
	Full vs. no vaccination		Partial vs. no vaccination	
	Unadjusted	Adjusted ^c	Unadjusted	Adjusted ^c
Overall	87 (83, 89)	87 (83, 89)	43 (37, 48)	42 (36, 48)
Age, y				
18-64	89 (77, 95)	90 (79, 95)	44 (27, 57)	43 (26, 57)
≥65	88 (84, 91)	88 (84, 91)	47 (41, 53)	46 (39, 51)
VHA defined priority group				
1-4	87 (79, 92)	87 (80, 92)	52 (42, 61)	51 (40, 60)
5-6	84 (72, 90)	83 (71, 90)	44 (30, 56)	45 (30, 56)
7-8	85 (69, 93)	83 (64, 92)	22 (-3, 41)	24 (-2, 43)
Race or ethnic group				
Black	92 (82, 96)	91 (81, 96)	37 (16, 52)	30 (7, 47)
White	83 (78, 88)	84 (78, 88)	44 (36, 51)	46 (39, 53)
Sex				
Male	87 (83, 90)	87 (83, 90)	42 (36, 48)	41 (34, 46)
Urban-rural				
Rural	87 (76, 93)	87 (76, 93)	45 (30, 57)	46 (31, 58)
Urban	84 (78, 88)	83 (78, 88)	38 (30, 45)	36 (27, 44)
BMI				
Obese	84 (75, 90)	83 (74, 89)	29 (15, 40)	27 (12, 39)
Underlying medical conditions				
Congestive heart failure	67 (10, 88)	71 (17, 90)	47 (8, 70)	49 (9, 72)
Chronic kidney disease	86 (53, 96)	87 (56, 96)	51 (23, 69)	47 (15, 67)
Diabetes mellitus	90 (81, 94)	89 (80, 94)	36 (20, 49)	34 (17, 48)
Hypertension	85 (78, 89)	85 (79, 90)	35 (24, 45)	36 (24, 45)
Immunocompromised	65 (32, 82)	67 (35, 83)	33 (6, 52)	37 (11, 55)

Abbreviations: BMI, body mass index; CMS, Centers for Medicare and Medicaid Services; ICD-10, International Classification of Diseases 10th Revision; VA, Veterans Affairs; VE, vaccine effectiveness.

^aSince 2020, for VHA enrolled patients with Medicare who have either tested positive for SARS-Cov-2 at a VHA facility or who have a COVID-19 medical claim in Medicare (ICD-10 codes B97.29 [“Other coronavirus”] and U07.1 [“COVID-19”] diagnosis code in inpatient, skilled nursing facility, institutional outpatient, hospice, and carrier/Part B files), the VHA receives the patients’ Medicare data with a 4-5 week lag time [REF <https://vaww.virec.research.va.gov/VACMS/Medicare/COVID19-Data.htm>].

^bSee Supplemental Table 1 for definitions of variables in this table.

^cThe adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.

Supplemental Table 5. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection by Type of Diagnostic Test^a

	VE, % (95% CI)			
Overall	Full vs. no vaccination		Partial vs. no vaccination	
	Unadjusted	Adjusted ^b	Unadjusted	Adjusted ^b
PCR test	95 (93, 96)	92 (89, 94)	68 (64, 70)	53 (49, 58)
Antigen test	96 (90, 99)	97 (90, 99)	54 (33, 69)	62 (42, 75)

Abbreviations: BMI, body mass index; VE, vaccine effectiveness; VHA, Veterans Health Affairs.

^aSee Supplemental Table 1 for definitions of variables in this table.

^bThe adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.

References

1. FDA. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine [Available from: <https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19>].
2. FDA. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine [Available from: <https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid>].
3. Affairs DoV. Department of Veterans Affairs COVID-19 National Summary [Available from: <https://www.accesstocare.va.gov/Healthcare/COVID19NationalSummary>].
4. Affairs TUSSCoV. BREAKING: Bipartisan Bill Expanding Vaccine Access for Vets & Families Signed Into Law [Available from: <https://www.veterans.senate.gov/newsroom/majority-news/breaking-bipartisan-bill-expanding-vaccine-access-for-vets-and-families-signed-into-law>].
5. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-15.
6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-16.
7. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-29.
8. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. 2021;384(15):1412-23.
9. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet*. 2021;397(10286):1725-35.
10. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(13):495-500.
11. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥ 65 Years - United States, January-March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(18):674-9.
12. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *Bmj*. 2021;373:n1088.

13. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. *JAMA*. 2021.
14. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. *Clin Infect Dis*. 2021;72(2):340-50.
15. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. *Lancet Oncol*. 2020;21(10):1309-16.
16. Vahidy FS, Nicolas JC, Meeks JR, Khan O, Pan A, Jones SL, et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population. *BMJ Open*. 2020;10(8):e039849.
17. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Jr., Skanderson M, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. *PLoS Med*. 2020;17(9):e1003379.
18. Abedi V, Olulana O, Avula V, Chaudhary D, Khan A, Shahjouei S, et al. Racial, Economic and Health Inequality and COVID-19 Infection in the United States. *medRxiv*. 2020.
19. CDC. COVID Data Tracker [Available from: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends>]. .
20. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. *JAMA*. 2020;324(19):1939-40.
21. McDermott D, Hudman, J., Cox, C. The Veteran Health Administration's Role During the COVID-19 Response [Available from: <https://www.healthsystemtracker.org/brief/the-veteran-health-administrations-role-during-the-covid-19-response/>].